https://www.pharmaceutical-technology.com/data-insights/oberotatug-ravtansine-oxford-biotherapeutics-gastric-cancer-likelihood-of-approval/
Oberotatug ravtansine is under clinical development by Oxford BioTherapeutics and currently in Phase I for Gastric Cancer.
gastric cancerravtansineoxfordbiotherapeuticslikelihood